Renaissance Technologies
CSTL icon

Renaissance Technologies’s Castle Biosciences CSTL Stock Holding History

Renaissance Technologies’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.85M Sell
371,200
-161,600
-30% -$3.6M 0.01% 1128
2026
Q1 		$13.1M Buy
532,800
+39,700
+8% +$1.3M 0.02% 829
2025
Q4 		$19.2M Sell
493,100
-69,500
-12% -$2.24M 0.03% 618
2025
Q3 		$12.8M Sell
562,600
-107,900
-16% -$2.19M 0.02% 963
2025
Q2 		$13.7M Sell
670,500
-30,700
-4% -$568K 0.02% 889
2025
Q1 		$14M Buy
701,200
+16,200
+2% +$401K 0.02% 832
2024
Q4 		$18.3M Buy
685,000
+195,438
+40% +$5.95M 0.03% 715
2024
Q3 		$14M Buy
489,562
+188,062
+62% +$4.79M 0.02% 870
2024
Q2 		$6.56M Buy
301,500
+96,800
+47% +$2.16M 0.01% 1140
2024
Q1 		$4.53M Buy
204,700
+92,300
+82% +$2.01M 0.01% 1480
2023
Q4 		$2.43M Buy
112,400
+5,600
+5% +$98.6K ﹤0.01% 1836
2023
Q3 		$1.8M Sell
106,800
-65,600
-38% -$1.15M ﹤0.01% 1931
2023
Q2 		$2.37M Buy
172,400
+136,000
+374% +$2.76M ﹤0.01% 1884
2023
Q1 		$827K Buy
36,400
+14,300
+65% +$349K ﹤0.01% 2598
2022
Q4 		$520K Buy
22,100
+5,100
+30% +$118K ﹤0.01% 2930
2022
Q3 		$443K Sell
17,000
-400
-2% -$11.2K ﹤0.01% 2997
2022
Q2 		$382K Sell
17,400
-7,600
-30% -$177K ﹤0.01% 3313
2022
Q1 		$1.12M Sell
25,000
-109,281
-81% -$4.52M ﹤0.01% 2662
2021
Q4 		$5.76M Buy
+134,281
New +$7.02M 0.01% 1437
2021
Q2 		– Sell
-27,500
Closed -$1.88M – 3503
2021
Q1 		$1.88M Buy
+27,500
New +$2.07M ﹤0.01% 2271
2020
Q4 		– Sell
-3,900
Closed -$201K – 3427
2020
Q3 		$201K Sell
3,900
-38,936
-91% -$1.73M ﹤0.01% 3109
2020
Q2 		$1.61M Buy
42,836
+9,636
+29% +$329K ﹤0.01% 2296
2020
Q1 		$990K Buy
+33,200
New +$1M ﹤0.01% 2430

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies's CSTL Position: Q2 2026 in Review

Renaissance Technologies reduced its Castle Biosciences (CSTL) stake by 30% in Q2 2026, selling an estimated $3.6M and leaving 371,200 shares worth $8.85M. The position accounts for 0.01% of the portfolio, ranked #1128.

Renaissance Technologies first reported a position in CSTL in Q1 2020 and has held it in 23 quarters since. The position peaked at $19.2M in Q4 2025. 176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Renaissance Technologies held 371,200 shares of Castle Biosciences worth $8.85M as of Q2 2026.
  • Renaissance Technologies sold 161,600 Castle Biosciences shares in Q2 2026, an estimated $3.6M.
  • Castle Biosciences made up 0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1128 holding.
  • Renaissance Technologies first reported a position in Castle Biosciences in Q1 2020 and has held it in 23 quarters since.
  • Renaissance Technologies's Castle Biosciences position peaked at $19.2M in Q4 2025.
  • 176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.